ProStrakan increases focus on Specialty Pharma model with sale of its Drug Discovery Unit (ProSkelia) to Galapagos - 22/12/2006
Click to download press release
ProStrakan announces the disposal of Zindaclin to Crawford Healthcare - 12/12/2006
Click to read more
ProStrakan announces an exclusive licence agreement with Ferring to distribute Rectogesic™ and Tostran™ in CEE, Russia and CIS - 11/12/2006
Click to read more
ProStrakan announces positive results from pivotal Phase III study on Sancuso™ (transdermal granisetron patch) - 6/12/2006
Click to read more
ProStrakan announces first milestone in bone related diseases collaboration - 6/12/2006
Click to read more
ProStrakan announces completion of US$9 million (£4.7 million) outright purchase of key worldwide rights to Rectogesic™ and Tostran™ - 29/11/2006
Click to read more
ProStrakan announces an exclusive collaboration with Novartis in the field of bone related diseases - 27/9/2006
Click to read more
ProStrakan announces US$9 million (£4.7 million) outright purchase of worldwide rights to Tostran™ and Rectogesic™ - 27/9/2006
Click to read more
ProStrakan announces an exclusive agreement with Gedeon Richter to distribute Rapinyl™ in CEE - 25/7/2006
Click to read more
ProStrakan announces exclusive licence and collaboration agreement with Amgen to develop and commercialise compounds for renal disease - 13/7/2006
Click to read more
ProStrakan extends Tostrex™ and Rectogesic™ rights to Russia and the CIS - 22/6/2006
Click to read more
Annual information update for period 16 June 2005 up to and including 11 May 2006 - 11/5/2006
Click to read more
Annual Report 2005 and Annual General Meeting Circular and Notice 2006 - 13/4/2006
Click to read more
EU's fastest growing healthcare company opens new global Headquarters - 23/1/2006
Click to read more